An orthoFab-Ig BsAb, ZW-25, targeting two nonoverlapping epitopes of HER2, was generated by using Azymetric and orthoFab-Ig methods [46], which is currently in phase I study for patients with HER2-expressing cancers (Table 1) [47]. The gene discussed is ERBB2; the disease is cancer.